insiderdelta
CoverageForm 410-K10-Q8-K13D13G13F

GOVX · Geovax Labs, Inc. - Financials

Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.

Price · GOVX

1Y3Y5YMax
Sign in to download
AnnualQuarterly

Income Statement

Line itemQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Revenue----------
Cost of Revenue----------
Gross Profit----------
R&D$3.90M-$5.04M$4.73M$5.35M-$7.40M$4.28M$4.43M-
SG&A$1.37M-$1.33M$1.54M$1.69M-$1.24M$1.09M$1.46M-
Total Operating Expenses$5.27M-$6.37M$6.27M$7.04M-$8.64M$5.36M$5.88M-
D&A$12.1K---$16.9K---$19.6K-
Operating Income($5.27M)-($6.37M)($5.42M)($5.41M)-($5.85M)($5.06M)($5.88M)-
Interest Expense--$0$0--$0$7.3K--
Income Tax$0---$0-----
Net Income($5.26M)-($6.32M)($5.37M)($5.36M)-($5.82M)($5.06M)($5.85M)-
EPS - Basic($2.62)-($7.75)($8.75)($11.25)-($22.75)($49.75)($61.75)-
EPS - Diluted----------

Balance Sheet

Line itemQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Cash & Equivalents$1.27M$3.09M$5.01M$3.09M$7.44M$5.51M$8.59M$1.56M$768.9K$6.45M
Accounts Receivable-$0$0$532.8K$1.50M$659.4K$547.6K$300.7K--
Inventory----------
Accounts Payable$1.43M$790.8K$976.4K$1.83M$2.40M$1.85M$2.15M$3.98M$1.88M$2.80M
Current Assets$2.43M$5.31M$6.52M$5.14M$10.61M$7.93M$10.87M$3.84M$2.86M$7.89M
Total Assets$2.98M$6.34M$6.73M$5.35M$10.83M$8.16M$11.11M$4.10M$3.36M$9.28M
Current Liabilities$2.29M$1.94M$1.82M$2.53M$2.94M$3.11M$2.61M$6.40M$3.30M$3.52M
Long-term Debt----------
Total Liabilities$2.49M$2.52M---$3.11M----
Stockholders' Equity$493.8K$3.83M$4.91M$2.82M$7.90M$5.05M$8.50M($2.31M)$54.3K$5.76M
Retained Earnings($156.08M)($150.82M)($146.40M)($140.08M)($134.71M)($129.36M)($121.09M)($115.28M)($110.21M)($104.36M)

Cash Flow

Line itemQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Operating Cash Flow($3.54M)---($5.97M)---($5.68M)-
Investing Cash Flow$0---$0-----
Financing Cash Flow$1.72M---$0-----
CapEx$0---$0-----
Free Cash Flow($3.54M)---($5.97M)-----

Ratios

MetricQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Profitability
Gross margin----------
Operating margin----------
EBITDA margin----------
Net margin----------
Free cash flow margin----------
FCF / Net income0.67---1.11-----
R&D / Revenue----------
SG&A / Revenue----------
Effective tax rate----------
Return on assets-176.4%--93.9%-100.4%-49.5%--52.3%-123.7%-174.2%-
Return on equity-1065.7%--128.8%-190.3%-67.8%--68.4%219.3%-10778.7%-
Return on invested capital----------
Liquidity
Current ratio1.062.743.572.033.622.554.170.600.872.24
Quick ratio1.062.743.572.033.622.554.170.600.872.24
Cash ratio0.551.592.751.222.531.773.290.240.231.83
Leverage
Debt / Equity----------
Debt / Assets----------
Debt / EBITDA----------
Interest coverage--------694.2x--
Equity multiplier6.041.661.371.901.371.621.31-1.7761.871.61
Liabilities / Assets0.830.40---0.38----
Efficiency
Asset turnover----------
Inventory turnover----------
Days sales outstanding----------
Days inventory outstanding----------
Days payable outstanding----------
Cash conversion cycle----------
Valuation
P / E----------
P / B----------
P / S----------
EV / EBITDA----------
Growth
Revenue growth (YoY)----------
Revenue CAGR (3y)----------
Revenue CAGR (5y)----------
Gross profit growth (YoY)----------
Operating income growth (YoY)2.4%--8.9%-7.0%8.1%-31.9%18.1%-37.8%-
Net income growth (YoY)1.8%--8.7%-6.0%8.4%-30.8%14.6%-44.9%-
EPS growth (YoY)----------
EPS CAGR (3y)----------
EPS CAGR (5y)----------
FCF growth (YoY)40.7%---------
FCF CAGR (5y)----------
Book value growth (YoY)-93.7%-24.2%-42.3%-14451.9%-12.4%-6.7%--99.8%-78.3%

Peer comparison

Same SIC group: Pharmaceutical Preparations

CompanyRevenue (last FY)Net marginROE
LLY$65.18B31.7%77.8%
UTHR$3.18B41.9%18.8%
PFE$62.58B12.4%9.0%
ZTS$9.47B28.2%80.2%
VRTX$12.00B32.9%21.2%

Comparing GeoVax Labs against the 5 most active filers in the same SIC group.